Critical Outcome Technologies Grants Stock Options

Critical Outcome Technologies Inc. (COTI) (TSX VENTURE:COT) announced today that
pursuant to an existing consulting agreement, the Board of Directors granted
200,000 stock options (Options) to Dr. Brent Norton who is also a director of
the Company, on October 15, 2013.


The Options are exercisable at a price of $0.24 and have a five year expiry
term. The Options vest as follows: 50,000 immediately and 50,000 on each of
December 1, 2013, March 1, 2014 and June 1, 2014. 


About Critical Outcome Technologies Inc. (COTI)

COTI is a leading-edge technology company specializing in accelerating the
discovery and development of small molecules - dramatically reducing the time
and cost to bring new drugs to market. COTI'S proprietary artificial
intelligence system, CHEMSAS(R), utilizes a series of predictive computer models
to identify compounds with a high probability of being successfully developed
from disease specific drug discovery through chemical optimization and
preclinical testing. These compounds are targeted for a variety of diseases,
particularly those for which current treatments are either lacking or
ineffective.


Follow @CriticalOutcome on Twitter at http://twitter.com/CriticalOutcome 

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Critical Outcome Technologies Inc.
Dr. Wayne Danter
President & CEO
519-858-5157
wdanter@criticaloutcome.com
www.criticaloutcome.com


Heisler Communications
Trevor Heisler
Investor Relations
416-500-8061
trevor@heislercommunications.com

Cotinga Pharmaceuticals (TSXV:COT)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024